Wakefield Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Wakefield Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.06M	Buy	70,404 +29,055	+70%	+$1.67M	0.91%	30
2026 Q1	$2.51M	Buy	+41,349	New	+$2.41M	0.66%	44
2025 Q1	–	Sell	-60,226	Closed	-$3.41M	–	201
2024 Q4	$3.41M	Buy	+60,226	New	+$3.37M	1.15%	31
2023 Q1	–	Sell	-4,439	Closed	-$319K	–	161
2022 Q4	$319K	Buy	+4,439	New	+$335K	0.14%	146
2021 Q2	–	Sell	-39,379	Closed	-$2.49M	–	157
2021 Q1	$2.49M	Buy	39,379 +2,187	+6%	+$136K	1%	28
2020 Q4	$2.31M	Sell	37,192 -2,382	-6%	-$146K	0.97%	35
2020 Q3	$2.39M	Sell	39,574 -203	-0.5%	-$12.2K	1.12%	30
2020 Q2	$2.34M	Sell	39,777 -7,856	-16%	-$470K	1.12%	26
2020 Q1	$2.65M	Buy	47,633 +2,640	+6%	+$161K	1.43%	11
2019 Q4	$2.89M	Sell	44,993 -4,195	-9%	-$240K	1.2%	14
2019 Q3	$2.49M	Sell	49,188 -16,236	-25%	-$763K	1.09%	35
2019 Q2	$2.97M	Sell	65,424 -8,109	-11%	-$378K	1.17%	34
2019 Q1	$3.51M	Buy	73,533 +5,056	+7%	+$252K	1.27%	26
2018 Q4	$3.56M	Buy	+68,477	New	+$3.68M	1.54%	11

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wakefield Asset Management's BMY Position: Q2 2026 in Review

Wakefield Asset Management increased its Bristol-Myers Squibb (BMY) stake by 70% in Q2 2026, buying an estimated $1.67M and bringing the position to 70,404 shares worth $4.06M. The position accounts for 0.91% of the portfolio, ranked #30.

Wakefield Asset Management first reported a position in BMY in Q4 2018 and has held it in 14 quarters since. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Wakefield Asset Management held 70,404 shares of Bristol-Myers Squibb worth $4.06M as of Q2 2026.
Wakefield Asset Management bought 29,055 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.67M.
Bristol-Myers Squibb made up 0.91% of Wakefield Asset Management's portfolio in Q2 2026, its #30 holding.
Wakefield Asset Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 14 quarters since.
2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Wakefield Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.